Buprenorphine in the Treatment of Opioid Dependence

Applied Pharmacology:
Clinical Use of Buprenorphine for the Treatment of Opioid Dependence

Amass L, Bickel WK, Crean JP, Blake J, and Higgins ST. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (136):217–225, 1998.

Amass L, Bickel WK, Higgins ST, and Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Disorders (13):33–45, 1994.

Amass L, Bickel WK, Higgins ST, and Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences (54):1,215–1,228, 1994.

Amass L, Kamien JB, and Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence (58):143–152, 2000.

Anderson F, Paluzzi P, Lee J, Huggins G, and Svikis D. Illicit use of clonidine in opiate-abusing pregnant women. Obstetrics and Gynecology (90):790–794, 1997.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, and Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics (3):72–78, 1988.

Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, and Johnson RE. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology and Experimental Therapeutics (47):47–53, 1988.

Bickel WK, Amass L, Crean JP, and Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (146):111–118, 1999.

Conway T and Balson A. Concomitant abuse of clonidine and heroin. Southern Medical Journal (86):954–956, 1993.

Diamant K, Fischer G, Schneider C, Lenzinger E, Pezawas L, Schindler S, and Eder H. Outpatient opiate detoxification treatment with buprenorphine: Preliminary investigation. European Addiction Research (4):198–202, 1998.

Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, and Stitzer ML. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence (45):81–91, 1997.

Fischer G, Johnson RE, Eder H, Yagsch R, Peternell A, Wehinger M, Langer M, and Aschauer HN. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction (95):239–244, 2000.

Fudala PJ, Jaffe JH, Dax EM, and Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics (47):525–534, 1990.

Johnson RE, Cone EJ, Henningfield JE, and Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clinical Pharmacology and Therapeutics (46):335–343, 1989.

Johnson RE, Jaffe JH, and Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association (267):2,750–2,755, 1992.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, and Bigelow GE. A placebo-controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence (40):17–25, 1995.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, and Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug and Alcohol Dependence (40):27–35, 1995.

Kosten TR, Schottenfeld R, Ziedonis D, and Falchion J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous Mental Disorders (181):358–364, 1993.

Lange WR, Fudala PJ, Dax EM, and Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependence (26):19–28, 1990.

Ling W, Wesson DR, Charuvastra C, and Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry (53):401–407, 1996.

Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Santos E, Casadonte P, Fye C, Stine S, Wang RIH, and Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction (93):475–486, 1998.

Mello NK, Mendelson JH, and Kuehnle JC. Buprenorphine effects on human heroin self-administration: An operant analysis. Journal of Pharmacology and Experimental Therapeutics (223):30–39, 1982.

Metzger DS, Woody GE, McLellan AT, O'Brien CP, Drawl P, Nasalize H, DePhilippis D, Stolley P, and Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: An 18-month prospective study. Journal of Acquired Immune Deficiency Syndromes (6):1,049–1,056, 1993.

O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, and Rounsaville B. Three methods of opiate detoxification in a primary care setting: A randomized trial. Annals of Internal Medicine (127):526–530, 1997.

Petry NM, Bickel WK, and Badger GJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clinical Pharmacology and Therapeutics (66):306–314, 1999.

Reynaud M, Tracqui A, Petit G, Potard D, and Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combination. American Journal of Psychiatry (155):448–449, 1998.

Rosen MI, Wallace EA, McMahon TJ, Pearsall R, Woods SW, Price LH, and Kosten TR. Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone. Drug and Alcohol Dependence (35):141–149, 1994.

Schuh KJ, Walsh SL, and Stitzer ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (145):162–174, 1999.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry (151):1,025–1,030, 1994.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (116):401–406, 1994.

Tracqui A, Kintz P, and Ludes B. Buprenorphine-related deaths among drug addicts in France: A report on 20 fatalities. Journal of Analytical Toxicology (22):430–434, 1998.